| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 385 | 2020 |
| Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. J Grøndahl-Hansen, HA Peters, WL Van Putten, MP Look, H Pappot, ... Clinical cancer research: an official journal of the American Association …, 1995 | 235 | 1995 |
| EAU-ESMO Consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort†: under the auspices of the EAU … JA Witjes, M Babjuk, J Bellmunt, HM Bruins, TM De Reijke, M De Santis, ... European urology 77 (2), 223-250, 2020 | 167 | 2020 |
| Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study M Quist, M Rørth, S Langer, LW Jones, JH Laursen, H Pappot, ... Lung Cancer 75 (2), 203-208, 2012 | 160 | 2012 |
| Oestrogen receptor β over expression in males with non-small cell lung cancer is associated with better survival BG Skov, BM Fischer, H Pappot Lung Cancer 59 (1), 88-94, 2008 | 158 | 2008 |
| Telemedicine and e-health solutions for COVID-19: patients' perspective N Pappot, GA Taarnhøj, H Pappot Telemedicine and e-Health 26 (7), 847-849, 2020 | 130 | 2020 |
| The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria E Rønne, H Pappot, J Grøndahl‐Hansen, G Høyer‐Hansen, T Plesner, ... British journal of haematology 89 (3), 576-581, 1995 | 116 | 1995 |
| First-in-human uPAR PET: imaging of cancer aggressiveness M Persson, D Skovgaard, M Brandt-Larsen, C Christensen, J Madsen, ... Theranostics 5 (12), 1303, 2015 | 108 | 2015 |
| Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer HJ Nielsen, H Pappot, IJ Christensen, N Brünner, O Thorlacius-Ussing, ... Bmj 316 (7134), 829-830, 1998 | 100 | 1998 |
| Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis B Bonnesen, H Pappot, J Holmstav, BG Skov Lung Cancer 66 (3), 314-318, 2009 | 94 | 2009 |
| Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications H Pappot, H Gardsvoll, J Romer, AN Pedersen, J Grondahl-Hansen, ... BIOLOGICAL CHEMISTRY HOPPE SEYLER 376, 259-259, 1995 | 94 | 1995 |
| Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients H Pappot, G Høyer-Hansen, E Rønne, HH Hansen, N Brünner, K Danø, ... European Journal of Cancer 33 (6), 867-872, 1997 | 92 | 1997 |
| EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU … A Horwich, M Babjuk, J Bellmunt, HM Bruins, TM De Reijke, M De Santis, ... Annals of Oncology 30 (11), 1697-1727, 2019 | 82 | 2019 |
| Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer LH Iversen, O Thorlacius-Ussing Thrombosis and haemostasis 87 (03), 402-408, 2002 | 80 | 2002 |
| High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria DJ Araten, HT Thaler, L Luzzatto Thrombosis and haemostasis 93 (01), 88-91, 2005 | 74 | 2005 |
| Safety, dosimetry, and tumor detection ability of 68Ga-NOTA-AE105: first-in-human study of a novel radioligand for uPAR PET imaging D Skovgaard, M Persson, M Brandt-Larsen, C Christensen, J Madsen, ... Journal of Nuclear Medicine 58 (3), 379-386, 2017 | 70 | 2017 |
| The use of wearables in clinical trials during cancer treatment: systematic review UL Beauchamp, H Pappot, C Holländer-Mieritz JMIR mHealth and uHealth 8 (11), e22006, 2020 | 67 | 2020 |
| Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy S Mustjoki, R Alitalo, RW Stephens, A Vaheri Thrombosis and haemostasis 81 (05), 705-710, 1999 | 66 | 1999 |
| Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer CE Almasi, K Brasso, P Iversen, H Pappot, G Høyer‐Hansen, K Danø, ... The Prostate 71 (8), 899-907, 2011 | 65 | 2011 |
| Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. J Grøndahl-Hansen, IJ Christensen, P Briand, H Pappot, HT Mouridsen, ... Clinical cancer research: an official journal of the American Association …, 1997 | 57 | 1997 |
